OBJECTIVE: To describe India's National Antimalarial Drug Resistance Monitoring System, measure the efficacy of first-line malaria treatments, and determine risk factors for treatment failure. METHODS: In 2009-2010, prospective studies with 28 days of follow-up were conducted at 25 sentinel sites. Patients infected with Plasmodium falciparum were given artesunate plus sulfadoxine-pyrimethamine (AS+SP); those infected with P. vivax were given chloroquine. Polymerase chain reaction was used to distinguish post-treatment reinfection from treatment failure. Isolates of P. falciparum were checked for dhfr and dhps mutations. FINDINGS: Overall, 1664 patients were enrolled. Kaplan-Meier survival analysis showed an efficacy of 98.8% for AS+SP. Most patients with P. falciparum parasitaemia cleared their parasitaemias within 24 hours of treatment initiation, but six, including four with treatment failure, remained parasitaemic after 72 hours. Double mutants in dhfr were found in 68.4% of the genotyped isolates. Triple or quadruple mutants in dhfr and mutations in dhps were rare. A daily dose of artesunate of < 3 mg per kg of body weight, age of less than 5 years, and fever at enrolment were associated with an increased risk of treatment failure. Chloroquine remained 100% efficacious and generally cleared P. vivax parasitaemias within 48 hours. Vomiting (seen in 47 patients) was the most common adverse event. CONCLUSION: India's National Antimalarial Drug Resistance Monitoring System provides wide coverage. The first-line antimalarials used in the country remain safe and efficacious. The treatment of malaria in young children and the relative benefits of age- and weight-based dosing need further exploration.
OBJECTIVE: To describe India's National Antimalarial Drug Resistance Monitoring System, measure the efficacy of first-line malaria treatments, and determine risk factors for treatment failure. METHODS: In 2009-2010, prospective studies with 28 days of follow-up were conducted at 25 sentinel sites. Patients infected with Plasmodium falciparum were given artesunate plus sulfadoxine-pyrimethamine (AS+SP); those infected with P. vivax were given chloroquine. Polymerase chain reaction was used to distinguish post-treatment reinfection from treatment failure. Isolates of P. falciparum were checked for dhfr and dhps mutations. FINDINGS: Overall, 1664 patients were enrolled. Kaplan-Meier survival analysis showed an efficacy of 98.8% for AS+SP. Most patients with P. falciparum parasitaemia cleared their parasitaemias within 24 hours of treatment initiation, but six, including four with treatment failure, remained parasitaemic after 72 hours. Double mutants in dhfr were found in 68.4% of the genotyped isolates. Triple or quadruple mutants in dhfr and mutations in dhps were rare. A daily dose of artesunate of < 3 mg per kg of body weight, age of less than 5 years, and fever at enrolment were associated with an increased risk of treatment failure. Chloroquine remained 100% efficacious and generally cleared P. vivax parasitaemias within 48 hours. Vomiting (seen in 47 patients) was the most common adverse event. CONCLUSION: India's National Antimalarial Drug Resistance Monitoring System provides wide coverage. The first-line antimalarials used in the country remain safe and efficacious. The treatment of malaria in young children and the relative benefits of age- and weight-based dosing need further exploration.
Authors: P M Wijeyaratne; P B Chand; N Valecha; B Shahi; T Adak; M A Ansari; J Jha; S Pandey; S Bannerjee; M B Bista Journal: Trans R Soc Trop Med Hyg Date: 2005-06 Impact factor: 2.184
Authors: Neena Valecha; Hema Joshi; Alex Eapen; John Ravinderan; Ashwani Kumar; Surendra Kumar Prajapati; Pascal Ringwald Journal: Trans R Soc Trop Med Hyg Date: 2006-02-28 Impact factor: 2.184
Authors: Ruchi Gupta; Neelima Mishra; Ashwani Kumar; Roma Rana; Bina Srivastava; P K Tyagi; Anupkumar R Anvikar; Neena Valecha Journal: Parasitol Res Date: 2015-06-27 Impact factor: 2.289
Authors: Naman K Shah; Charles Poole; Pia D M MacDonald; Bina Srivastava; Allan Schapira; Jonathan J Juliano; Anup Anvikar; Steven R Meshnick; Neena Valecha; Neelima Mishra Journal: Trop Med Int Health Date: 2013-04-30 Impact factor: 2.622
Authors: Anupkumar R Anvikar; Usha Arora; G S Sonal; Neelima Mishra; Bharatendu Shahi; Deepali Savargaonkar; Navin Kumar; Naman K Shah; Neena Valecha Journal: Indian J Med Res Date: 2014-02 Impact factor: 2.375
Authors: Sweta Mishra; Praveen K Bharti; Man M Shukla; Nazia A Ali; Sher S Kashyotia; Avdhesh Kumar; Akshay C Dhariwal; Neeru Singh Journal: Pathog Glob Health Date: 2017-05-26 Impact factor: 2.894
Authors: Naman K Shah; Allan Schapira; Jonathan J Juliano; Bina Srivastava; Pia D M MacDonald; Charles Poole; Anup Anvikar; Steven R Meshnick; Neena Valecha; Neelima Mishra Journal: Antimicrob Agents Chemother Date: 2013-04-15 Impact factor: 5.191